Green tea epigallocatechin-3-gallate suppresses autoimmune arthritis through indoleamine-2,3-dioxygenase expressing dendritic cells and the nuclear factor, erythroid 2-like 2 antioxidant pathway

Journal of Inflammation (United Kingdom)

Volumn 12, Issue 1, 2015, Pages

  Min, So Youn ^a   Yan, Mei ^a   Kim, Sang Bum ^b   Ravikumar, Sneha ^a,d   Kwon, Seong Ryuel ^a,c   Vanarsa, Kamala ^a,d   Kim, Ho Youn ^c   Davis, Laurie S ^a   Mohan, Chandra ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Inha University School of Medicine   (South Korea)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

Collagen induced arthritis; Green Tea ( ) epigallocatechin 3 gallate (EGCG); Nrf 2 signaling pathway; Regulatory T cells

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; EPIGALLOCATECHIN GALLATE; GAMMA INTERFERON; HEME OXYGENASE 1; IMMUNOGLOBULIN G2A ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTHRITIS; ARTICLE; B LYMPHOCYTE; BONE EROSION; CARTILAGE EROSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DENSITOMETRY; DISEASE SEVERITY; DRUG EFFECT; EROSION; ERYTHEMA; EX VIVO STUDY; FLOW CYTOMETRY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; LIMB SWELLING; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SKIN REDNESS; TH1 CELL; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

EID: 84941655224     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/s12950-015-0097-9     Document Type: Article

References (61)

1. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford). 2003;42 Suppl 2:ii11-16.
2. Lipsky PE. Why does rheumatoid arthritis involve the joints? N Engl J Med. 2007;356:2419-20.
3. Sun HB. Mechanical loading, cartilage degradation, and arthritis. Ann N Y Acad Sci. 2010;1211:37-50.
4. Sheikh A, Naqvi SH, Naqvi SH, Sheikh K. Itraconazole: its possible role in inhibiting angiogenesis in rheumatoid arthritis. Med Hypotheses. 2012;79:313-4.
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
6. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27-34.
7. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2.
8. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy. 2015;35:520-35.
9. Gargiulo G, Capodanno D, Longo G, Capranzano P, Tamburino C. Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther. 2014;12:1185-203.
10. Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag Care. 2013;19:s267-272.
11. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-35.
12. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v48-54.
13. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11:276-89.
14. Singh R, Akhtar N, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. [corrected]. Life Sci. 2010;86:907-18.
15. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther. 2010;12:208.
16. Wu D, Wang J, Pae M, Meydani SN. Green tea EGCG, T cells, and T cell-mediated autoimmune diseases. Mol Aspects Med. 2012;33:107-18.
17. Peng A, Ye T, Rakheja D, Tu Y, Wang T, Du Y, et al. The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int. 2011;80:601-11.
18. Wang J, Ren Z, Xu Y, Xiao S, Meydani SN, Wu D. Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets. Am J Pathol. 2012;180:221-34.
19. Kim HR, Rajaiah R, Wu QL, Satpute SR, Tan MT, Simon JE, et al. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr. 2008;138:2111-6.
20. Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A. 1999;96:4524-9.
21. Lin SK, Chang HH, Chen YJ, Wang CC, Galson DL, Hong CY, et al. Epigallocatechin-3-gallate diminishes CCL2 expression in human osteoblastic cells via up-regulation of phosphatidylinositol 3-Kinase/Akt/Raf-1 interaction: a potential therapeutic benefit for arthritis. Arthritis Rheum. 2008;58:3145-56.
22. Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD. Collagen-induced arthritis. Curr Protoc Immunol. 2010;Chapter 15:Unit 15 15 11-25.
23. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2:1269-75.
24. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106:2375-81.
25. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev. 1990;118:193-232.
26. Min SY, Hwang SY, Park KS, Lee JS, Lee KE, Kim KW, et al. Induction of IL-10-producing CD4∈+∈CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther. 2004;6:R213-219.
27. Davis LS, Cush JJ, Schulze-Koops H, Lipsky PE. Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells. Arthritis Res. 2001;3:54-64.
28. Billiau A. Interferon-gamma in autoimmunity. Cytokine Growth Factor Rev. 1996;7:25-34.
29. Jaen O, Rulle S, Bessis N, Zago A, Boissier MC, Falgarone G. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology. 2009;126:35-44.
30. Kumar KR, Zhu J, Bhaskarabhatla M, Yan M, Mohan C. Enhanced expression of stem cell antigen-1 (Ly-6A/E) in lymphocytes from lupus prone mice correlates with disease severity. J Autoimmun. 2005;25:215-22.
31. Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+∈CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther. 2008;10:R11.
32. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-74.
33. von Bubnoff D, Scheler M, Wilms H, Wenzel J, von Bubnoff N, Hacker G, et al. Indoleamine 2,3-dioxygenase-expressing myeloid dendritic cells and macrophages in infectious and noninfectious cutaneous granulomas. J Am Acad Dermatol. 2011;65:819-32.
34. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2006;290:H1862-1870.
35. Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med. 2011;51:744-54.
36. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006;116:984-95.
37. Fu Z, Zhen W, Yuskavage J, Liu D. Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br J Nutr. 2011;105:1218-25.
38. Gillespie K, Kodani I, Dickinson DP, Ogbureke KU, Camba AM, Wu M, et al. Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sci. 2008;83:581-8.
39. Ahn SC, Kim GY, Kim JH, Baik SW, Han MK, Lee HJ, et al. Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. Biochem Biophys Res Commun. 2004;313:148-55.
40. Rogers J, Perkins I, van Olphen A, Burdash N, Klein TW, Friedman H. Epigallocatechin gallate modulates cytokine production by bone marrow-derived dendritic cells stimulated with lipopolysaccharide or muramyldipeptide, or infected with Legionella pneumophila. Exp Biol Med (Maywood). 2005;230:645-51.
41. Hu ZQ, Toda M, Okubo S, Hara Y, Shimamura T. Mitogenic activity of (-)epigallocatechin gallate on B-cells and investigation of its structure-function relationship. Int J Immunopharmacol. 1992;14:1399-407.
42. Wilasrusmee C, Kittur S, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes. J Altern Complement Med. 2002;8:467-75.
43. Wu D, Guo Z, Ren Z, Guo W, Meydani SN. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med. 2009;47:636-43.
44. Liu D, Li P, Song S, Liu Y, Wang Q, Chang Y, et al. Pro-apoptotic effect of epigallo-catechin-3-gallate on B lymphocytes through regulating BAFF/PI3K/Akt/mTOR signaling in rats with collagen-induced arthritis. Eur J Pharmacol. 2012;690:214-25.
45. Saleh F, Raghupathy R, Asfar S, Oteifa M, Al-Saleh N. Analysis of the effect of the active compound of green tea (EGCG) on the proliferation of peripheral blood mononuclear cells. BMC Complement Altern Med. 2014;14:322.
46. Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, et al. CD4∈+∈CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2517-21.
47. Oh S, Rankin AL, Caton AJ. CD4∈+∈CD25+ regulatory T cells in autoimmune arthritis. Immunol Rev. 2010;233:97-111.
48. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003;48:1452-60.
49. Wong CP, Nguyen LP, Noh SK, Bray TM, Bruno RS, Ho E. Induction of regulatory T cells by green tea polyphenol EGCG. Immunol Lett. 2011;139:7-13.
50. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181:5396-404.
51. Maicas N, Ferrandiz ML, Brines R, Ibanez L, Cuadrado A, Koenders MI, et al. Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxid Redox Signal. 2011;15:889-901.
52. Wruck CJ, Fragoulis A, Gurzynski A, Brandenburg LO, Kan YW, Chan K, et al. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis. 2011;70:844-50.
53. Park SY, Lee SW, Shin HK, Chung WT, Lee WS, Rhim BY, et al. Cilostazol enhances apoptosis of synovial cells from rheumatoid arthritis patients with inhibition of cytokine formation via Nrf2-linked heme oxygenase 1 induction. Arthritis Rheum. 2010;62:732-41.
54. Devesa I, Ferrandiz ML, Terencio MC, Joosten LA, van den Berg WB, Alcaraz MJ. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis Rheum. 2005;52:3230-8.
55. Benallaoua M, Francois M, Batteux F, Thelier N, Shyy JY, Fitting C, et al. Pharmacologic induction of heme oxygenase 1 reduces acute inflammatory arthritis in mice. Arthritis Rheum. 2007;56:2585-94.
56. Turley AE, Zagorski JW, Rockwell CE. The Nrf2 activator tBHQ inhibits T cell activation of primary human CD4 T cells. Cytokine. 2015;71:289-95.
57. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med. 2005;202:47-59.
58. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 2006;66:11580-4.
59. Kong X, Thimmulappa R, Kombairaju P, Biswal S. NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. J Immunol. 2010;185:569-77.
60. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol. 2012;2012:252460.
61. Jurgens B, Fuchs D, Reichenbach J, Heitger A. Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. Clin Immunol. 2010;137:1-4.